admin
Governor JB Pritzker told CBS this week that he has lost roughly 80 pounds taking a GLP‑1 medication and that Illinois now covers these weight‑loss and diabetes drugs for about 55,000 state employees. He called the treatment “life‑changing” and argued taxpayer‑funded coverage will save money by preventing diabetes. That sounds great for him — but when a governor turns a personal medical choice into a taxpayer program, voters deserve straight answers, not pep rallies.
Pritzker’s pitch: life‑changing — and budget‑saving?
The governor’s line is simple: GLP‑1 drugs curb appetite, help people lose weight, and fewer obese residents means fewer diabetes cases and lower long‑term costs. Nice sound bite. The reality is messier. Early state estimates pegged first‑year costs in the low hundreds of millions — one figure tossed around was $210 million — and later reporting put fiscal year spending at about $147 million. And remember, list prices for brand GLP‑1 or GIP/GLP‑1 drugs commonly run in the $12,000–$16,000 per year range. That’s real money up front, not vague “savings” years from now.
Who pays and who really benefits?
Coverage, enrollment, and accountability
The expansion rests on a change to the State Employees Group Insurance rules that lets the plan cover medically necessary injectable medicines for glucose control or weight loss. Pritzker says 55,000 state employees are eligible under the plan. But eligible does not mean enrolled, and enrolled does not mean still taking the drug a year from now. Taxpayers should see how many employees actually filled prescriptions, what drugs are on the formulary, what prior‑authorization rules exist, and how long people stay on therapy. Without that transparency, “we’ll save money” is just a slogan.
Politics and optics: timing isn’t accidental
Pritzker is running for a third term as governor and is widely floated as a 2028 presidential contender. He claims the policy was in place before he started treatment and that he isn’t promoting it for personal gain. Fine. But when a governor uses his platform to tout an expensive drug while taxpayers write the checks, expect political scrutiny. Telling people to consult a doctor while encouraging state plans to pay for a costly, long‑term therapy smells like a politician mixing public policy and personal branding — and taxpayers should be skeptical.
What taxpayers should demand next
If this policy is truly about saving money and improving health, the governor’s office and the Department of Central Management Services should publish the numbers: who’s enrolled, what the FY‑by‑FY claims look like, what drugs were paid for, and the assumptions behind earlier budget estimates. If GLP‑1 treatments are as miraculous as claimed, make the case with hard data — not press interviews. Until then, Illinoisans should treat “life‑changing” stories with a grain of salt and demand fiscal accountability from leaders who want the public to underwrite expensive medical trends.
